EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates

Alican Bozdaş, Özge Özbaykal, Zeynep Bağlan Atalay, Sevde Nur Fırat, Mehmet Şeneş, Işılay Taşkaldıran

Frontiers in Endocrinology · 19.11.2026 · 17

DOI: 10.3389/fendo.2026.2004756 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Frontiers in Endocrinology, online erschienen am 19.11.2026. Verfasst von Alican Bozdaş und 5 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver-expressed antimicrobial peptide 2 (LEAP2) is an endogenous ghrelin-receptor antagonist implicated in metabolic regulation. Evidence in polycystic ovary syndrome (PCOS) is limited. We evaluated circulating LEAP2 according to PCOS status and phenotype and examined its metabolic and hormonal correlates.

Methods

This single-center, cross-sectional study with prospective recruitment included 64 women with PCOS and 24 controls without PCOS. Fasting serum LEAP2 was measured by enzyme-linked immunosorbent assay. Multivariable linear regression of log-transformed LEAP2 was adjusted for body mass index (BMI) and homeostasis model assessment of insulin resistance (HOMA-IR). Within PCOS, Spearman correlations were evaluated with false discovery rate correction.

Results

Median LEAP2 was higher in women with PCOS than in controls (0.493 [0.287–0.863] vs. 0.333 [0.227–0.439] ng/mL; p=0.027). After adjustment for BMI and HOMA-IR, PCOS was associated with a 60.5% higher LEAP2 concentration (ratio of geometric means, 1.605; 95% CI, 1.221–2.109; p=0.001). Adjusted LEAP2 was higher in both hyperandrogenic and non-hyperandrogenic PCOS than in controls. No statistically significant differences were detected across PCOS phenotypes, although substantial differences could not be excluded. Triglycerides were the only correlate remaining significant after false discovery rate correction (Spearman ρ=0.372; q=0.040). In a post hoc adjusted model, each triglyceride doubling was associated with a 52.9% higher LEAP2 concentration (ratio of geometric means, 1.529; 95% CI, 1.256–1.862; p<0.001).

Conclusion

Circulating LEAP2 is elevated in PCOS after adjustment for BMI and HOMA-IR. No significant phenotype differences were detected, although larger studies are needed. Its association with triglycerides suggests a potential link with altered lipid-related metabolic signaling.

Zitieren

APA

Bozdaş, A., Özbaykal, Ö., Atalay, Z. B., Fırat, S. N., Şeneş, M., & Taşkaldıran, I. (2026). Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2004756

Vancouver

Bozdaş A, Özbaykal Ö, Atalay ZB, Fırat SN, Şeneş M, Taşkaldıran I. Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2004756

BibTeX
@article{Bozda2026,
  author = {Bozdaş, Alican and Özbaykal, Özge and Atalay, Zeynep Bağlan and Fırat, Sevde Nur and Şeneş, Mehmet and Taşkaldıran, Işılay},
  title = {Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.2004756}
}
Kostenlos starten →